Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.49 |
| ▸ | ACACA | Q13085 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241775 | 0.90 | ACACB (0.44) | ACACBACACAKCNH2PDE10APDE2A | |
| SCHEMBL3268968 | 0.88 | ACACB (0.49) | ACACBACACAKCNH2CKS1BSKP1 | |
| SCHEMBL10202394 | 0.87 | HRH3 (0.46) | ACACBACACAKCNH2CKS1BSKP1 | |
| SCHEMBL3265602 | 0.82 | ACACB (0.44) | ACACBACACAKCNH2CKS1BSKP1 | |
| SCHEMBL3265718 | 0.79 | MALT1 (0.45) | ACACBACACAKCNH2CKS1BSKP1 | |
| SCHEMBL241458 | 0.79 | DRD3 (0.41) | PDE10A | |
| SCHEMBL5237624 | 0.79 | ALDH1A1 (0.53) | — | |
| SCHEMBL3268730 | 0.78 | FAAH (0.46) | ACACBACACAKCNH2PDE10APDE2A | |
| SCHEMBL3265670 | 0.78 | MAP4K4 (0.44) | ACACBACACAKCNH2PDE10AMAP4K4 | |
| SCHEMBL240267 | 0.78 | PDE10A (0.44) | ACACBACACAKCNH2PDE10APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACACB 1063/4885ACACA 1566/4885KCNH2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.